Investigational drug · Phase 2
Human Dopaminergic Progenitor Cells
Also called: NouvNeu001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson Disease, Parkinson Disease (PD).
Phase 2Last checked: Nov 20, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
19
Any phase or sponsor naming "Human Dopaminergic Progenitor Cells"
First trial start
2024
Jan 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Human Dopaminergic Progenitor Cells", any sponsor or status.
- Phase 117
Conditions studied
As listed on its trial records.
- Parkinson Disease
- Parkinson Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Human Dopaminergic Progenitor Cells" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePivotal-lookingRecruiting
BlueRock TherapeuticsIndustry
NCT06944522 · 102 participants (planned) · Start Jun 17, 2025 · Primary completion Oct 2028
Drug: bemdaneprocel · For: Parkinsons Disease (PD)
Sites: Scottsdale, Arizona; Sun City, Arizona; Little Rock, Arkansas · 43 sites in all
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Industry
NCT07166757 · 90 participants (planned) · Start Sep 22, 2025 · Primary completion Mar 30, 2028
Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection · For: Parkinson Disease (PD)
Sites: Shanghai, China
Nuwacell Biotechnologies Co., Ltd.Industry
NCT06978920 · 48 participants (planned) · Start Jun 6, 2025 · Primary completion Jul 1, 2026
Drug: Allogeneic dopaminergic neural precursor cell(NCR201) · For: Parkinson Disease
Sites: Hefei, China
iRegene Therapeutics Co., Ltd.Industry
NCT06167681 · 40 participants (planned) · Start Jan 17, 2024 · Primary completion Dec 2025
Drug: Human Dopaminergic Progenitor Cells · For: Parkinson Disease
Sites: Beijing, China; Wuhan, China
- The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's DiseaseActive, not recruiting
XellSmart Therapeutics (Shanghai) Co., Ltd.Industry
NCT07080775 · 39 participants · Start Aug 5, 2025 · Primary completion Jul 2027
Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection · For: Parkinson's Disease
Sites: Beijing, China
iRegene Therapeutics Co., Ltd.Industry
NCT07028632 · 30 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 2026
Drug: Human Dopaminergic Progenitor Cells · For: Parkinson Disease (PD)
Sites: Beijing, China
The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
NCT07911670 · 12 participants (planned) · Start Nov 23, 2026 · Primary completion Mar 2029
Drug: UX-DA003 · For: PARKINSON DISEASE (Disorder)
Sites: Hefei, China
- Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's DiseaseCompleted
BlueRock TherapeuticsIndustry
NCT04802733 · 12 participants · Start May 3, 2021 · Primary completion May 18, 2023
Drug: MSK-DA01 · For: Advanced Parkinson's Disease
Sites: Orange, California; New York, New York; Toronto, Canada
- A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBSNot yet recruiting
Nuwacell Biotechnologies Co., Ltd.Industry
NCT07896187 · 12 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: NCR201 · For: PARKINSON DISEASE (Disorder); Cell Therapy; Human Induced Pluripotent Stem Cells and 3 more
Sites: Beijing, China
- An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's DiseaseActive, not recruiting
Shanghai UniXell Biotechnology Co., LtdIndustry
NCT06778265 · 12 participants (planned) · Start Mar 1, 2025 · Primary completion Dec 2027
Drug: UX-DA001 · For: Parkinson Disease, Idiopathic
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
- AP-472Phase 21 trial
Appello Pharmaceuticals, Inc. · Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.